Efficacy
EVENTS, DISEASE PROGRESSION
The overall response rate was 100%. Ten patients (32%) achieved stringent CR, nine had CR (29%), eight (26%) had VGPR, and 4 (13%) had PR. Twenty-seven (87%) patients had ≥VGPR, the study’s primary endpoint. Details of response rates are summarized in Table Response assessment parameters of the study patients.At a median follow-up of 14 months (range: 8–21 months), nine patients had died, and five events of disease progression happened. PFS and OS at 12 months were 67.7% and 70.7%, respectively, in the intent-to-treat population. PFS at 12 months with or without ASCT in patients who had ≥VGPR (